$PETS earnings report

PetMeds Q2 net sales fell 19.4% to $35.8 million and net loss narrowed to $6.4 million, while adjusted EBITDA loss widened to $(3.6) million. AlphAI read Petmed Express's Second quarter ended September 30, 2026 (six months ended Septem filing as weak.

Second quarter ended September 30, 2026 (six months ended Septem

AlphAI · Earnings readPETS · Second quarter ended September 30, 2026 (six months ended September 30, 2026 also reported) · ended 2026-09-30

PetMeds Q2 net sales fell 19.4% to $35.8 million and net loss narrowed to $6.4 million, while adjusted EBITDA loss widened to $(3.6) million

↓Weak half-year

Net sales declined 19.4% year over year and the non-GAAP adjusted EBITDA loss widened by 57%. The GAAP net loss narrowed 24%, and the company attributes this to lower G&A and advertising, but gross profit fell and cash, total assets and equity all declined from the March 31, 2026 balance sheet.

Revenue
$76.8M
EPS · GAAP
$(0.60)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, Q2 (three months ended Sept 30, 2026)GAAP$35.77M–decrease of 19.4%
Cost of sales, Q2GAAP$25.97M––
Gross profit, Q2GAAP$9.80M––
General and administrative expenses, Q2GAAP$11.97M––
Advertising expenses, Q2GAAP$2.07M––
Depreciation and amortization, Q2GAAP$2.18M––
Total operating expenses, Q2GAAP$16.22M––
Loss from operations, Q2GAAP−$6.42M––
Interest (expense) income, net, Q2GAAP−$195K––
Other, net, Q2GAAP$194K––
Provision for income taxes, Q2GAAP$14K––
Net loss, Q2GAAP−$6.43M–24% decrease in net loss
Basic and diluted net loss per share, Q2GAAP$(0.31)––
Adjusted EBITDA, Q2non-GAAP−$3.64M–(57)%
Net sales, six months ended Sept 30, 2026GAAP$76.78M––
Cost of sales, six monthsGAAP$55.65M––
Gross profit, six monthsGAAP$21.14M––
General and administrative expenses, six monthsGAAP$23.16M––
Advertising expenses, six monthsGAAP$6.29M––
Depreciation and amortization, six monthsGAAP$4.33M––
Impairment of goodwill and intangible assets, six monthsGAAPnil (printed as a dash)––
Total operating expenses, six monthsGAAP$33.79M––
Loss from operations, six monthsGAAP−$12.65M––
Interest (expense) income, net, six monthsGAAP−$533K––
Other, net, six monthsGAAP$632K––
Total other income (expense), six monthsGAAP$99K––
Loss before provision for income taxes, six monthsGAAP−$12.55M––
Provision for income taxes, six monthsGAAP$27K––
Net loss, six monthsGAAP−$12.58M–71% decrease in net loss
Basic and diluted net loss per share, six monthsGAAP$(0.60)––
Adjusted EBITDA, six monthsnon-GAAP−$7.09M–(41)%
Cost to acquire a new customer, Q2 (as stated by CEO)other32% reduction from a year ago–32%
Net cash used in operating activities, six monthsGAAP−$8.74M––
Purchases of property and equipment, six monthsGAAP−$1.23M––
Net decrease in cash and cash equivalents, six monthsGAAP−$9.99M––

Capital returns

  • Dividends paid, six months ended Sept 30, 2026: printed as a dash (nil); six months ended Sept 30, 2025: $(23) thousand.
  • Cash paid for tax withholding on net settlement of restricted stock, six months: $(23) thousand (2026) versus $(238) thousand (2025).
  • Net cash used in financing activities, six months: $(23) thousand (2026) versus $(261) thousand (2025).
  • No share repurchase program activity is printed in the release.

What drove it

  • Company explanation: the Q2 net sales decrease of 19.4% was primarily driven by a decline in prescription medication sales and higher consumer promotional usage.
  • Company explanation: the lower Q2 net loss was primarily driven by lower general and administrative expenses and advertising expenses.
  • Company explanation: lower gross profit was primarily driven by unfavorable product mix shift and lower manufacturer rebates as a percentage of sales, partially offset by lower net freight costs per order.
  • Advertising expense fell from $4,341 thousand to $2,072 thousand in Q2, and G&A fell from $14,176 thousand to $11,968 thousand, per the statement of operations.
  • Prior-year six-month period included a $27,258 thousand impairment of goodwill and intangible assets, which is not present in the current six-month period.
  • Company states it has stabilized operations and is focused on transforming the core direct-to-consumer pharmacy business.

Concerns

  • Net sales declined 19.4% in Q2 and $76,785 thousand versus $95,544 thousand for the six months, a steep top-line contraction.
  • Adjusted EBITDA loss widened to $(3,643) thousand in Q2 from $(2,316) thousand, a 57% deterioration on the company's own non-GAAP measure.
  • Gross profit fell to $9,803 thousand from $12,415 thousand, and the release attributes this to product mix and lower manufacturer rebates as a percentage of sales.
  • Cash fell to $11,418 thousand from $21,412 thousand at fiscal year-end, and shareholders' equity fell to $16,862 thousand from $28,940 thousand.
  • Retained earnings turned negative at $(3,316) thousand at Sept 30, 2026, from $9,263 thousand at March 31, 2026.
  • Operating cash outflow for six months was $(8,744) thousand, and the filing prints no guidance for the coming periods.

What to watch

  • Whether net sales stabilize after the 19.4% Q2 decline, particularly prescription medication sales.
  • Gross profit trajectory given the company-cited product mix shift and lower manufacturer rebates as a percentage of sales.
  • Whether the advertising and G&A reductions continue, and how the 32% lower cost to acquire a new customer, as cited by the CEO, affects sales.
  • Adjusted EBITDA trend, since the non-GAAP loss widened even as the GAAP net loss narrowed.
  • Cash balance trajectory, which declined by $9,994 thousand in the six months.

Balance sheet and cash flow

  • Cash and cash equivalents at Sept 30, 2026: $11,418 thousand, versus $21,412 thousand at March 31, 2026 (fiscal year-end comparison, not a prior-quarter figure).
  • Inventories at Sept 30, 2026: $6,303 thousand, versus $13,608 thousand at March 31, 2026.
  • Total assets at Sept 30, 2026: $59,403 thousand, versus $81,191 thousand at March 31, 2026.
  • Total liabilities at Sept 30, 2026: $42,541 thousand, versus $52,251 thousand at March 31, 2026.
  • Total shareholders' equity at Sept 30, 2026: $16,862 thousand, versus $28,940 thousand at March 31, 2026.
  • Accounts payable at Sept 30, 2026: $15,258 thousand, versus $20,906 thousand at March 31, 2026.
  • Sales tax payable at Sept 30, 2026: $18,927 thousand, versus $22,261 thousand at March 31, 2026.
  • Retained earnings moved from $9,263 thousand at March 31, 2026 to $(3,316) thousand at Sept 30, 2026.
  • Net cash used in operating activities for six months ended Sept 30, 2026: $(8,744) thousand, versus $(14,445) thousand in the prior-year period.
  • Cash paid for income taxes, net of refunds, six months: $(137) thousand (2026) versus $66 thousand (2025).

Analysis

PetMeds reported second-quarter results for the period ended September 30, 2026 in which net sales were $35,770 thousand, down from $44,364 thousand a year earlier, a decline of 19.4%. The company attributes the decline primarily to lower prescription medication sales and higher consumer promotional usage. Six-month net sales were $76,785 thousand against $95,544 thousand in the prior-year period, but the filing does not print a six-month percentage change. The top-line contraction is the dominant feature of the period and the release gives no guidance to frame it.

Profitability moved in two directions. The GAAP net loss narrowed to $(6,434) thousand, or $(0.31) per diluted share, from $(8,520) thousand, or $(0.41) per share, a 24% reduction. The company links this to lower general and administrative expenses, which fell to $11,968 thousand from $14,176 thousand, and advertising expenses, which fell to $2,072 thousand from $4,341 thousand. Gross profit moved the other way, declining to $9,803 thousand from $12,415 thousand, which the company attributes to unfavorable product mix and lower manufacturer rebates as a percentage of sales, partly offset by lower net freight costs per order. The non-GAAP adjusted EBITDA loss widened to $(3,643) thousand from $(2,316) thousand, a 57% increase in the loss, so the GAAP and non-GAAP measures present different directions for the quarter.

For the six months, the GAAP net loss was $(12,579) thousand against $(42,672) thousand, a change of 71% that reflects the absence of the prior-year $27,258 thousand goodwill and intangible impairment. Adjusted EBITDA for the six months was $(7,091) thousand against $(5,012) thousand, a 41% larger loss. The comparison of the two six-month periods is therefore distorted by the impairment in the prior year, while the adjusted measure shows the underlying loss widening.

The balance sheet and cash flow show a business drawing down resources. Cash and cash equivalents were $11,418 thousand at September 30, 2026 against $21,412 thousand at March 31, 2026, and net cash used in operating activities for six months was $(8,744) thousand. Inventories fell to $6,303 thousand from $13,608 thousand, which contributed to operating cash flow, while accounts payable and sales tax payable declined. Total assets were $59,403 thousand against $81,191 thousand at fiscal year-end, and shareholders' equity was $16,862 thousand against $28,940 thousand. No dividends were paid in the six months, and the release prints no share repurchases.

The CEO describes the company as having stabilized operations and sets a plan to transform the direct-to-consumer pharmacy business. He cites a 32% reduction in the cost to acquire a new customer from a year ago, a figure the release states but does not reconcile to a reported line. The release provides no forward guidance, so the company's stated plan cannot be measured against prior targets in this filing.

Management, verbatim

We have stabilized the operations of the business and our focus now is on transforming our core direct-to-consumer pharmacy business and making PetMeds a leaner, more profitable company at the size we are today.

Jeff Willard, Chief Executive Officer and President of PetMeds

this quarter we cut our cost to acquire a new customer by 32% from a year ago.

Jeff Willard, Chief Executive Officer and President of PetMeds

Not in the filing

stated, not guessed
  • Forward guidance for revenue, gross margin, operating expenses or tax rate: not provided in the filing.
  • Prior-year and prior-quarter comparison for six-month net sales percentage change: not printed.
  • Gross margin percentage for Q2 and six months: not printed.
  • Year-over-year percentage changes for gross profit, cost of sales, operating expense lines, loss from operations and total operating expenses: not printed.
  • Prior-quarter (Q1 FY2027) comparatives: not printed in the release.
  • Free cash flow: not printed.
  • Diluted share count reconciliation and per-share measures beyond the printed net loss per share: not printed.
  • Segment or product-line revenue breakdown: not provided.
  • Consensus estimates, analyst expectations and share-price reaction: not provided in the documents.
  • Dividend declared for the period: not printed (only dividends paid in the six-month cash flow statement).
  • Share repurchase activity: not printed.
  • Explanation of the 32% cost-to-acquire reduction beyond the CEO statement: not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about PETS earnings dates

When is Petmed Express's next earnings date?
AlphAI has no date for PETS yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.